Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Globe Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤LX2006 improved mean mFARS 4.26 points over two years versus propensity-matched controls
- ➤LX2006 participants with 36-month follow-up showed mean mFARS improvement exceeding 4 points from baseline
- ➤LX2006 cardiac and neurologic measures showed durable, continued improvement over time
- ➤Lexeo will present cardiovascular gene therapy data at AHA and ICAR conferences in November
Expert Statements
Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics
“We are pleased to have multiple presentations at both AHA and ICAR, reflecting continued momentum across our cardiovascular and neurological genetic disease programs”
Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics
“We are particularly excited about the new mFARS data that will be presented at ICAR, which demonstrate durable neurologic benefit following LX2006 treatment and continued improvement over time”
Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics
“These findings build upon the encouraging cardiac benefits previously observed and further strengthen our belief that LX2006 has the potential to address the multisystem manifestations of Friedreich ataxia”
Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies
New LX2006 data to be presented at ICAR demonstrating cardiac and neurologic benefit up to 36 months, showing sustained or deepening improvement in mFARS outcomes over time
Get started
Create a free account to read the full story.